The Mast Cell Leukemia drugs in development market research report provides comprehensive information on the therapeutics under development for Mast Cell Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Mast Cell Leukemia. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Mast Cell Leukemia and features dormant and discontinued products.
GlobalData tracks five drugs in development for Mast Cell Leukemia by five companies/universities/institutes. The top development phase for Mast Cell Leukemia is phase ii with four drugs in that stage. The Mast Cell Leukemia pipeline has five drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Mast Cell Leukemia pipeline products market are: Blueprint Medicines, Seagen and Novartis.
The key targets in the Mast Cell Leukemia pipeline products market include Mast/Stem Cell Growth Factor Receptor Kit (Proto Oncogene c Kit or Tyrosine Protein Kinase Kit or v Kit Hardy Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog or Piebald Trait Protein or CD117 or KIT or EC 2.7.10.1), Platelet Derived Growth Factor Receptor (PDGFR or EC 2.7.10.1), and Platelet Derived Growth Factor Receptor Alpha (Alpha Type Platelet Derived Growth Factor Receptor or CD140 Antigen Like Family Member A or Platelet Derived Growth Factor Receptor 2 or CD140a or PDGFRA or EC 2.7.10.1).
The key mechanisms of action in the Mast Cell Leukemia pipeline product include Mast/Stem Cell Growth Factor Receptor Kit (Proto Oncogene c Kit or Tyrosine Protein Kinase Kit or v Kit Hardy Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog or Piebald Trait Protein or p145 c Kit or CD117 or KIT or EC 2.7.10.1) Inhibitor with four drugs in Phase II. The Mast Cell Leukemia pipeline products include three routes of administration with the top ROA being Oral and three key molecule types in the Mast Cell Leukemia pipeline products market including Small Molecule, and Antisense Oligonucleotide.
Mast Cell Leukemia overview
Mast cell leukemia (MCL) is a rare and aggressive type of blood cell cancer. It is a subtype of systemic mastocytosis (SM) and caused by the abnormal growth of cells from myeloid progenitor cells. Symptoms include lethargy and weakness, fainting, flushing, fever, tachycardia, losing more than 10 percent of body weight, diarrhea, nausea, and vomiting. MCL diagnosis requires fulfillment of diagnostic criteria for SM plus at least 20% immature/atypical mast cells on bone marrow smear. Treatment may include medications known as monoclonal antibodies, tyrosine kinase inhibitors, and forms of chemotherapy.
For a complete picture of Mast Cell Leukemia’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
